Search Results

You are looking at 1 - 10 of 117 items for :

  • pituitary tumors x
Clear All
Open access

Solène Castellnou, Alexandre Vasiljevic, Véronique Lapras, Véronique Raverot, Eudeline Alix, Françoise Borson-Chazot, Emmanuel Jouanneau, Gérald Raverot and Hélène Lasolle

Introduction Cushing’s disease is a rare disorder defined as chronic hypercortisolism due to a corticotropin-secreting pituitary tumor (corticotroph tumor) ( 1 ). Chronic cortisol excess is responsible for multisystem morbidity, contributing

Open access

G Giuffrida, F Ferraù, R Laudicella, O R Cotta, E Messina, F Granata, F F Angileri, A Vento, A Alibrandi, S Baldari and S Cannavò

Introduction Pituitary tumors (PT) are generally benign and slow growing, but in some cases, they can present with the invasion of dura, bone or surrounding structures in the absence of malignant features. In these cases, they are defined as

Open access

Jintao Hu, Qingbo Chen, Xiao Ding, Xin Zheng, Xuefeng Tang, Song Li and Hui Yang

Background Pituitary adenoma (PA) is the second most common brain tumor. Except for prolactinoma, pituitary tumors associated with acromegaly (growth hormone-secreting) and Cushing’s disease (adrenocorticotropic hormone-secreting) as well as

Open access

Aida Javanbakht, Massimo D’Apuzzo, Behnam Badie and Behrouz Salehian

adenomas, metastatic tumors, when detected, are more likely to be located in the posterior pituitary. This likely accounts for diabetes insipidus (DI) being more common in patients with Pit Met than patients with other pituitary pathology. The exact

Open access

Adrian F Daly, David A Cano, Eva Venegas-Moreno, Patrick Petrossians, Elena Dios, Emilie Castermans, Alvaro Flores-Martínez, Vincent Bours, Albert Beckers and Alfonso Soto-Moreno

thyrotropinomas are rarer ( 1 , 2 , 3 ). Treatment of pituitary adenomas varies according to the pituitary adenoma sub-type. Responses to therapy are variable due to heterogeneity among patient profiles and tumor characteristics. For instance, acromegaly

Open access

Tao Mei, Jianhe Zhang, Liangfeng Wei, Xingfeng Qi, Yiming Ma, Xianhua Liu, Shaohua Chen, Songyuan Li, Jianwu Wu and Shousen Wang

Introduction Pituitary adenomas (PA) are among the most common intracranial tumors, accounting for 10–15% of primary intracranial tumors ( 1 ). It has been confirmed by positron emission tomography and tumor cell culture experiments that PA

Open access

Morten Winkler Møller, Marianne Skovsager Andersen, Christian Bonde Pedersen, Bjarne Winther Kristensen and Frantz Rom Poulsen

Introduction Pituitary adenomas (PAs) account for 10–25% of intracranial tumors ( 1 , 2 , 3 ). They arise from adenohypophyseal cells, despite their benign nature, 25–55% of PAs show invasive growth ( 4 ), expanding into suprasellar ( 5

Open access

Adrian F Daly, Liliya Rostomyan, Daniela Betea, Jean-François Bonneville, Chiara Villa, Natalia S Pellegata, Beatrice Waser, Jean-Claude Reubi, Catherine Waeber Stephan, Emanuel Christ and Albert Beckers

.5%) ( 5 ). The pituitary tumors in acromegaly are generally macroadenomas (>10 mm in diameter), and nearly half of patients have local tumor invasion at diagnosis. Many studies have examined the molecular genetic pathophysiology of acromegaly. The best

Open access

Benedetta Zampetti, Erika Grossrubatscher, Paolo Dalino Ciaramella, Edoardo Boccardi and Paola Loli

much larger population of patients with pituitary-dependent ACTH hypersecretion. The need for an effective distinction comes from the observation that (more frequently than previously believed) tumors-secreting ACTH ectopically cause a syndrome, which

Open access

Paula Bruna Araujo, Leandro Kasuki, Carlos Henrique de Azeredo Lima, Liana Ogino, Aline H S Camacho, Leila Chimelli, Márta Korbonits and Monica R Gadelha

) ( 3 ), which is characterized by the presence of pituitary adenomas in two or more members of the same family in the absence of other syndromic clinical features. AIP appears to act as a tumor suppressor gene (TSG) ( 3 ). It is a cytoplasmic protein